Dividend yield shows the relationship between the annual dividend paid per share by a company divided by share price of a company. While is clear that dividend yield represents relationship between dividend and share price of a company, how to identify a high dividend yield share. Though there is no standard definition of high dividend yield, any dividend yield which is close to 5% should be considered as a high dividend yield while dividend yield in the range of 8 to 10 percent should be considered as extraordinary dividend yield stock.
What is the use of high dividend yield stocks for investors? Can an investor utilise it in the process of financial planning? How should an investor allocate such stocks in the investment portfolio? High dividend yield stocks ensure that the investor keeps on receiving decent yearly cash flow assuming that dividend is given once every year. While an investor can reinvest the money received as dividend, the optimal use of dividend can be made in a different way.
Top Blue Chip Companies To Own In Right Now: American Capital Mortgage Investment Corp (MTGE)
American Capital Mortgage Investment Corp., incorporated on March 15, 2011, is a real estate investment trust (REIT). The Company�� investment objective is to provide risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. It invests to achieve this objective by selectively constructing and managing a mortgage investment portfolio consisting of asset classes that, when properly financed and hedged, are designed to produce risk adjusted returns across a variety of market conditions and economic cycles. In December 2013, American Capital Mortgage Investment Corp, through its subsidiary acquired Residential Credit Solutions, Inc.
The Company is externally managed and advised by American Capital MTGE Management, LLC. American Capital MTGE Management, LLC is an indirect subsidiary of American Capital, LLC, which is a wholly portfolio company of American Capital, Ltd.
Advisors' Opinion:- [By Arie Goren]
American Capital Mortgage Investment Corp. (MTGE)
American Capital Mortgage Investment Corp. operates as a real estate investment trust (REIT) in the United States.
- [By Sean Williams]
These spreads are what have allowed mREITs to pay out double-digit yields for years now. However, with spreads tightening as mortgage rates hit their highest levels in two years, dividend cuts are beginning to cycle through the sector. American Capital Agency (NASDAQ: AGNC ) , Annaly Capital Management� (NYSE: NLY ) , and American Capital Mortgage Investment (NASDAQ: MTGE ) all recently cut their dividends�in lieu of smaller investment profits.
Top 5 High Dividend Companies To Invest In Right Now: Glatfelter (GLT)
P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.
Advisors' Opinion:- [By CRWE]
Glatfelter (NYSE:GLT) reported that the previously announced presentation by Dante C. Parrini, Chairman and Chief Executive Officer, at the Deutsche Bank Global Industrials and Basic Materials Conference on Wednesday, June 13, 2012 will be available via a live web cast.
- [By Eric Volkman]
Glatfelter (NYSE: GLT ) has a new asset in its portfolio. The company announced it has finalized the acquisition of Germany-based Dresden Papier, which according to the American firm is "the leading global supplier of nonwoven wallpaper base materials."
Top 5 High Dividend Companies To Invest In Right Now: Orbital Sciences Corporation(ORB)
Orbital Sciences Corporation develops and manufactures small and medium-class rockets and space systems for commercial, military, and civil government customers. The company operates in three segments: Launch Vehicles, Satellites and Space Systems, and Advanced Space Programs. The Launch Vehicles segment develops and produces small-class launch vehicles that place satellites into low-Earth orbit; interceptor launch vehicles for missile defense systems, including interceptor boosters; and target launch vehicles, such as suborbital rockets and their principal subsystems, as well as payloads carried by vehicles used in the development and testing of missile defense systems. The Satellites and Space Systems segment develops and produces communications satellites that provide cable and direct-to-home television distribution, business data network connectivity, regional mobile telephony, and other space-based communications services; and science and remote sensing satellites tha t are used to conduct space-related scientific research, collect imagery and other remotely-sensed data about the Earth, carry out interplanetary and other deep-space exploration missions, and demonstrate new space technologies. This segment also provides space systems and subsystems, including satellite command and data handling, and attitude control and structural subsystems; and a range of space-related technical services, including analytical, engineering, and production services for space-related science and defense programs. The Advanced Space Programs segment develops and produces human-rated systems to be used in earth orbit, planetary exploration, and other space missions; and small and medium-class satellites and related systems used primarily for national security space missions and related technology demonstration programs. It operates in the United States, Europe, Mexico, South America, Australia, and east Asia. The company was founded in 1982 and is headquarter ed in Dulles, Virginia.
Advisors' Opinion:- [By Chris Katje]
For those unfamiliar with Orbital Sciences (ORB), the company is a leader in space missions and satellite services. The company operates its business in three segments: launch vehicles, satellites and space systems, and advanced space programs. The company's contract with the International Space System, huge backlog, and human space exploration could send shares much higher than current levels.
- [By Jake L'Ecuyer]
Shares of Orbital Sciences (NYSE: ORB) got a boost, shooting up 15.38 percent to $30.66 after the company and Allian Techsystems' (NYSE: ATK) Aerospace and Defense Groups agreed to combine to create Orbital ATK.
- [By Quick Pen]
The aerospace sector is increasingly becoming competitive. The acquisition proposal comes at a time when another Dulles-based industry player Orbital Sciences (ORB) plans to combine with the defense segment of Alliant Techsystems��(ATK) and emerge as a stronger new entity named Orbital ATK. The defense space has been vastly dominated by the United Launch Alliance, which is a joint venture between Chicago-based aircraft major Boeing (BA) and Lockheed Martin. However, after the $5 billion merger deal to form Orbital ATK is complete, the industry will grow more competitive.
- [By Lee Jackson]
Orbital Sciences Corp.‘s (NYSE: ORB) 2013 results and 2014 outlook point to the revenue growth and high free cash flow potential of the franchise. The Jefferies analysts see opportunities for new orders, 7% revenue growth and acceleration of free cash flow, and they expect shares to continue to advance. The company develops and manufactures small and medium-class rockets and space systems for commercial, military and civil government customers. Jefferies raises its price target from $27 to $31. The consensus number is $33.17. The stock closed on Friday at $28.27.
Top 5 High Dividend Companies To Invest In Right Now: Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
No comments:
Post a Comment